|
|
|
| Analysis of Clinical Efficacy and Safety of Patients with Parkinson's Disease Treated with Metoprolol and Pramipexole |
| CHEN Dan |
| The Central Hospital of Panjin, Liaoning Panjin 124010, China |
|
|
|
|
Abstract Objective: To study the effect of treatment with midazolam and pramipexole on clinical efficacy and safety in patients with Parkinson's disease. Methods: A total of 95 patients with Parkinson's disease treated in our department from May 2015 to March 2017 were selected. The random number table was divided into control group (n=42) and study group (n=53). Patients in the control group were treated with metoprolol, and patients in the study group were treated with metopa and pramipexole. The UPDRS II, UPDRS III, and UPDRS IV scores before and after treatment were compared between the two groups of patients, and the excellent rate of treatment and the occurrence of adverse reactions during treatment were compared. Results: There was no significant difference in the UPDRS II, UPDRS III, and UPDRS IV scores between the two groups (P>0.05). The UPDRS II and UPDRS III scores at the 8th and 12th week after treatment were significantly lower in the study group than in the control group. The scores at the 12th week after treatment in both groups were significantly lower than those at the 8th week after treatment. The scores at the 8th and 12th week after treatment were significantly lower than those before treatment in both groups and were statistically significant. Difference (P<0.05). The rate of excellent treatment in the control group was 59.52%, which was significantly lower than that in the study group (88.68%). There was a statistically significant difference (χ2=4.504, P<0.05). The incidence of adverse reactions in the control group was significantly higher than that in the study group (23.81%), which was 7.55%, with statistical significance (χ2=5.309, P<0.05). Conclusions: The treatment of Parkinson's disease patients with midazolam combined with pramipexole can improve the clinical curative effect, which is beneficial to improve the daily living ability and motor function of patients, and has a higher safety.
|
|
|
|
|
|
[1] 王龚奋飞,梁朵朵,米亚塞尔.阿布来提,等.奥拉西坦联合美多芭治疗帕金森病临床观察[J].中国实用神经疾病杂志,2014,17(13):30~31.
[2] 叶华.王耀光.金哲如,等.普拉克索联用美多芭治疗原发性帕金森病的疗效观察[J].现代实用医学,2015,27(10):1307~1309.
[3] 纪新博,顾申红,容琼文,等.盐酸普拉克索配合神经节苷脂对帕金森患者血清炎症因子及运动功能的影响[J].现代中西医结合杂志,2016,25(24):2693~2695.
[4] 王美娥,张鹏,宋杰,等.美多芭联合普拉克索治疗帕金森病的有效性及安全性探究[J].中国实用医药,2016,11(6):154~155.
[5] 杨永,张雪玲.普拉克索与溴隐亭治疗帕金森病的对照研究[J].中国药业,2014,23(15):25~26.
[6] 王永春,王钊,刘童童,等.美多芭对帕金森病患者血小板中五羟色胺影响的临床研究[J].中国医师进修杂志,2015,38(zl):27~28.
[7] 刘志强,朴钟源,刘永丹,等.美多芭联合盐酸普拉克索治疗帕金森病对运动功能的作用[J].中国实用神经疾病杂志,2015,18(15):94~95.
[8] 马宇,李兴贵,展群岭,等.普拉克索与美多芭合用配合心理治疗应用于帕金森病合并睡眠障碍患者的效果[J].检验医学与临床,2018,15(1):30~33. |
|
|
|
2018, Vol. 24 
